The COVID-19 pandemic sparked international concern about vulnerabilities in the global supply chain and disrupted the production of crucial pharmaceutical ingredients around the world. In a strained, but resilient market, two promising vaccine candidates boasting nearly 95% effectiveness rose to the top of various formulations. While their sponsors seek Emergency Use Authorization (EUA) from the Food and Drug Administration, the rest of the American health care system is preparing for vaccine deployment and mass immunization. This briefing will explore how our supply chain must respond to manufacture millions of doses and then swiftly deliver them to administration sites. Panelists will also illustrate the steps these stakeholders might take in the first 48 hours after an Emergency Use Authorization is approved.
